The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.

Novo Nordisk filed an FDA application for weekly CagriSema after trials showed up to 22.7% weight loss versus placebo.

Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the ...

Eli Lilly ( LLY 1.19%) and Novo Nordisk ( NVO 2.44%) are two of the leading companies in the fast-growing GLP-1 weight loss ...

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, ...